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ABSTRACT 
Treating serious bone trauma with an osteo-inductive agent such as bone 
morphogenetic proteins (BMPs) has been considered as an optimized option when 
delivered via a collagen sponge (CS). Previous work has shown that the BMP 
concentration and release rate from approved CS carriers is difficult to control with 
precision. Here we presented the fabrication of a recombinant fusion protein from 
recombinant human-like collagen (HLC) and human BMP-2 (hBMP2). The fusion 
protein preserved the characteristic of HLC allowing the recombinant protein to be 
expressed in Yeast (such as Pichia pastoris GS115) and purified rapidly and easily with 
mass production after methanol induction. It also kept the stable properties of HLC and 
hBMP2 in the body fluid environment with good biocompatibility and no cytotoxicity. 
Moreover, the recombinant fusion protein fabricated a vertical through-hole structure 
with improved mechanical properties, and thus facilitated migration of bone marrow 
mesenchymal stem cells (MSCs) into the fusion materials. Furthermore, the fusion 
protein degraded and released hBMP-2 in vivo allowing osteoinductive activity and the 
enhancement of utilization rate and the precise control of the hBMP2 release. This 
fusion protein when applied to cranial defects in rats was osteoinductively active and 
improved bone repairing enhancing the repairing rate 3.5- fold and 4.2- fold when 
compared to the HLC alone and the control, respectively. There were no visible 
inflammatory reactions, infections or extrusions around the implantation sites observed. 
Our data strongly suggests that this novel recombinant fusion protein could be more 
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1. Introduction 
Treating serious bone trauma is a clinical challenge and always requires the assist of 
osteo-inductive agents such as bone morphogenetic proteins (BMPs) [1]. BMPs 
normally provide a primordial signal for osteoprogenitor cells to differentiate into 
osteoblasts and then to form the bone extracellular matrix (ECM) [2] while BMPs retain 
at the site of injury and render an initial support which allows cells to attach and further 
regenerate the lost architecture on the ECM [3]. More than 20 types of BMPs have now 
been cloned, and BMP-2 and BMP-7 have the strongest osteogenic activity and are the 
most effective osteogenic factors [4-6]. However, BMP-2 is a water-soluble protein and 
easily diffused (the half-life is only 7~16 minutes [7]) after being implanted into a 
defect site, resulting in low osteogenic efficiency. Normally a carrier system that can 
load with BMP-2 in an appropriate low dose and with a sustained release profile is 
substantially needed [8-15].  
Collagen, being the most abundant protein in mammalian connective tissue and the 
main non-mineral component of bone, can gradually degrade, has good 
biocompatibility, and can be easily molded into porous materials. Collagen has been a 
good candidate to release a growth factor slowly [16]. Animal collagen used as a 
sustained release carrier for BMP-2 can prolong the release time of BMP-2 and enhance 
the osteoinductive activity of BMP-2, thereby improve the bone repairing [17-23]. 
However, the methods used to combine BMP-2 with collagen are mainly through 
soaking collagen in BMP-2 solution [17-22]. Due to the low affinity of growth factors 
and collagen [24], the release rate of BMP-2 is difficult to control and the utilization of 
BMP-2 is incomplete. In addition, animal-derived collagens have potential viral risk 
and immunogenicity [25]. Therefore, designing a novel safer carrier with low 
immunogenicity and precise control of BMP-2 release is the key to improve the BMP-
2 utilization for bone repairing. 
The human-like collagen (HLC) is a recombinant protein and obtained by genetic 
engineering on the basis of a natural human collagen repeat sequence of "Gly-Pro-Hyp", 
"Gly-Pro-Xaa" or "Gly-Xaa-Yaa" (Xaa, Yaa represents one random amino acid) [26]. 
HLC keep the properties of the natural collagen with the advantages of high porosity, 
high elastic modulus, good processing performance, no viral risk and low 
immunogenicity, and have been widely studied in hemostatic sponge [26], skin injury 
treatments [27], and tissue engineering vascular scaffolds [28]. We recently used 
glutamine transaminase (TG) to enzymatically cross-link this HLC to obtain a specially 
structured HLC sponge with enhanced mechanical strength and vertical pore structure, 
and then loaded this HLC with BMP-2 to repair bone. Although the new HLCs, which 
can now be mass-produced in our lab, overcome limitations of commercially available 
animal-derived collagens as a delivery system for bone repairing, the release rate of 
BMP-2 through this HLC delivery system is still difficult to control and the rapid 
release of a higher dose of BMP-2 (i.e, 5µg) could even induce the bone hyperplasia 
[29].  
In this study, we fabricated a novel fusion protein using the recombinant HLC as a 
carrier for hBMP2 to address the above-mentioned concerns. This fusion protein was 
expressed in Pichia pastoris GS115, purified and mass-produced. The structure and 
properties of this fusion protein were furthered tested by scanning electron microscope 
(SEM), mechanical analysis, swelling behavior analysis, enzymatic degradation and 
cellular assessment assays. A cranial defect animal model was then used to test the 
effectiveness of this novel recombinant fusion protein. The novel fusion protein 
fabricated in this study greatly extend the ability of HLC in loading and releasing BMP-
2 and would be beneficial in the treatment of bone defects, and the methods developed 
in this study could also release other growth factors and be used in other medical 
applications. 
 
2. Materials and methods 
2.1. Design of the HLC-hBMP2 fusion protein 
To develop the HLC-hBMP2 fusion protein for controllable release of hBMP-2 and 
with osteogenic activity in bone defect repairing, the modified gene code of the human 
collagen type I (Col I) was used, synthesized and linked with the hBMP-2 gene. Then 
Pichia pastoris GS115 was transformed by the plasmid with HLC-hBMP2 gene and the 
HLC-hBMP2 fusion protein was then obtained through fermentation of yeast. In order 
to ensure that the BMP-2 and the HLC were not affected by a steric hindrance from 
each other and can be freely folded, a linker peptide rich in small molecule amino acids 
such as (G)n, (GGGGS)n, (n=1-4) was designed between the HLC and the hBMP2. 
Structures of the designed fusion proteins were obtained through the I-TASSER server 
(https://zhanglab.ccmb.med.umich.edu/I-TASSER/). From all designed proteins, we 
chose one HLC-hBMP2 sequence in which the hBMP2 active site was fully exposed 
(Fig. 1). In this study, we compared this novel fused protein with both the recombinant 
HLC and the HLC sponge absorbed hBMP2 through glutamine transaminase (TG) link 
in our previous work [29]. 
 
Fig. 1. Tertiary structure prediction of HLC-hBMP2 fusion protein with different 
connecting peptide. (a) Spherical protein conformation enveloping the hBMP2 active 
site; (b-d) Two proteins interfering with each other while folding; (e) hBMP2 connected 
with the end at the spiral structure of HLC. 
2.2. Construction of the HLC and the HLC-hBMP2 fusion protein expression 
plasmids 
The gene sequence of HLC (Supporting Information-Sequence 1) with an Xho I site at 
the 5’-end and EcoRI site at the 3’-end was chemically synthesized. The HLC gene 
fragment was inserted between the Xho I and EcoRI sites at the sequence of the pPIC9K 
plasmid, thus the pPIC9K-HLC plasmid was constructed. Another structural gene for 
GGGGS-hBMP2 (Supporting Information-Sequence 2) with an EcoRI site at the 5’-
end and Not I site at the 3’-end was also chemically synthesized. The GGGGS-hBMP2 
gene fragment was then inserted between the EcoRI and Not I site at the sequence of 
pPIC9K-HLC. The gene expression plasmid (pPIC9K-HLC-hBMP2) for the HLC-
hBMP2 fusion protein was then constructed. In order to verify whether the expression 
vector contained target fragments, the pPIC9K-HLC-hBMP2 plasmid was analyzed by 
digesting with Xho I and Not I. The gene sequencing of the pPIC9K-HLC-hBMP2 
plasmid was tested. 
2.3. Expression and purification of the HLC and the HLC-hBMP2 fusion protein 
Plasmid pPIC9K-HLC-hBMP2 was linearized using Sal I and transformed into Pichia 
pastoris GS115 by electroporation (Elector Cell Manipulator, Bio-Rad, USA) at 1500V, 
200Ω, 25μF, 0.2cm cuvettes. The high expression strain was selected using minimal 
dextrose (MD) medium plates containing 0.25, 0.5, 1.0, 2.0, 2.5, 3.0, and 4.0 mg/mL of 
G418, and then cultivated in the yeast extract peptone dextrose (YPD) medium 
overnight at 30℃ and 250rpm. The culture was transferred into the Buffered glycerol 
complex medium (BMGY) and further cultured at 30℃ and 250rpm until the OD 600 
reached 2.0-8.0. After collected by centrifuging at about 4000 rpm for 3 min at 4℃, the 
cell pellets were diluted to an OD 600 of 1.0 in buffered methanol complex medium 
(BMMY). Methanol (0.5%) was added to the culture medium every day to induce 
protein expression, and one ml medium was collected every day to check the expression 
level and to determine the optimal time to harvest the target protein. 
The high expression strain was inoculated into fermenters (Shanghai Baoxing, 5L and 
150L fermenters). The culture conditions and culture media in the fermentor were 
shown in Table S1. After 5 days of fermentation, the expression culture was collected 
and centrifuged at 4℃ for 30 minutes. The supernatant was then collected and detected 
by SDS-PAGE in order to identify the HLC-hBMP2 protein. After that, the cell 
fragments were removed from the supernatant containing the HLC-hBMP2 by the 
immersion hollow fiber membrane (Tianjin Membrane Technology Co., Ltd.), and 
subsequently desalted by a 10kD cut-off filter (Tianjin Membrane Technology Co., 
Ltd.). In the end, the HLC-hBMP2 with purity above 95% was obtained by an ion-
exchange chromatography using an SPFF strong cation exchange column and AKTA 
purification system (GE, USA). At the same time, we used the same method to obtain 
the purified HLC as a control. 
2.4. Preparation of the HLC and the HLC-hBMP2 scaffold 
The HLC-hBMP2 fusion protein was a soluble protein. The EDC/NHS/MES system 
was used to cross-link HLC-hBMP2 to obtain an insoluble scaffold material of HLC- 
hBMP2. Firstly, HLC-hBMP2 fusion protein was dissolved in double-distilled water 
(2% w/v), immediately adding 0.1M EDC, 0.02M NHS, and 0.1M MES. The bubbles 
in the solution were removed by centrifugation after thoroughly blending, and then the 
solution was statically placed at 4℃ for 24 hours. Finally, the HLC-hBMP2 hydrogel 
obtained by cross-linking was vacuum freeze-dried and stored in a dryer for later use. 
The HLC scaffold was prepared as a control using the same method detailed as above. 
2.5. Characterization of the HLC-hBMP2 scaffold 
2.5.1. Morphological characterization 
The general morphology of HLC-hBMP2 fusion material was obtained by a digital 
camera. The microscopic morphology of the HLC-hBMP2 fusion material was further 
observed by a scanning electron microscope (SEM, Hitachi s-4700, Japan). 
2.5.2. Mechanical characterization 
The mechanical properties of HLC and HLC-hBMP2 porous sponge materials were 
tested using a material testing machine (Instron-5542, Canton, MA, USA). The sample 
was made into a cylinder of 8mm diameter×5mm height, and the chuck was placed at 
a speed of 0.5mm/min to approach and compress the sample. The compression was 
stopped once the sample was irreversibly deformed. The elastic modulus of the HLC-
hBMP2 porous sponge was calculated from the generated force and displacement 
curves. 
2.5.3. Swelling behavior 
The swelling behavior of HLC-hBMP2 fusion material was tested in simulated body 
fluid (PBS) according to the method of Parmar et al. [30] to evaluate its stability. The 
HLC was used as the control. Briefly, HLC and HLC-hBMP2 fusion materials (n=6) 
were weighed and recorded as dry weight (Wd). Then the materials were immersed into 
the PBS to form hydrogels. Subsequently, the formed hydrogels soaked in the PBS 
solution were taken out at 2, 4, 6, 24, and 48 hours, respectively. After further washing 
with PBS 2 to 3 times, the wet weight (Ws) of formed hydrogel was weighed and 





2.5.4 Enzymatic Degradation Kinetics 
Enzymatic degradation was normally used as an accelerated measurement of material 
degradation [31]. Because the designed HLC backbone was originated from Col I, we 
therefore firstly used the Type I collagenase to test the enzymatic degradation of the 
HLC and the HLC-hBMP2 in vitro. We used Type II and Type IV collagenases as the 
control. In vivo enzymatic degradation evaluation of the HLC and the HLC-hBMP2 
was carried out in the later part of the study.  
Briefly, HLC and HLC-hBMP2 were made into cylinders of 8mm diameter×3mm 
height, approximate 30 mg per sample (n=6). Type I collagenase (100U/mL, Sigma), 
Type II collagenase (100U/mL, Sigma) or Type IV collagenase (100U/mL, Sigma) 
dissolved in PBS was added to sample according to 5 mg sample with 1 mL collagenase 
solution, respectively.  After the samples were incubated for 10, 30, 60, 120, 180 and 
240 min at 37°C, the digestion mixture was centrifuged at 18,000g for 1 min, then 50μL 
of the digestion solution was collected and stored at -20°C for analysis. The protein 
concentration in the release was detected using a BSA kit and a UV-visible 
spectrophotometer (BioRad). 
2.6. MSCs adhesion, proliferation and migration 
2.6.1 MSCs Culture 
Sprague Dawley (SD) rats (6-8 weeks old and 220-250g weight) were obtained from 
the animal holding unit, Northwest University. Bone marrow samples were harvested 
according to the project approval (No: ACUC2013015) by the Institutional Animal Care 
and Use Committee (IACUC), Northwest University. Bone marrow mesenchymal stem 
cells (MSCs) were obtained from the SD rats according to our previous studies [32, 33]. 
2.6.2 MSCs adhesion on the HLC-hBMP2 
Cell adhesion on the surface of the material was examined to test the cytocompatibility 
of the material. Briefly, 1×106 MSCs were seeded into each HLC- hBMP2 scaffold and 
incubated for 4 hours respectively. After that, the specimens were rinsed with PBS, 
fixed with 2.5% glutaraldehyde, and dehydrated in an ethanol solution of gradient 
concentration (i.e., 30, 50, 70, 90 and 100% respectively). After critical point drying, 
the specimens were eventually coated with gold-palladium. They were then examined 
by SEM. 
2.6.3 MSCs proliferation on the HLC-hBMP2 
In addition to cell adhesion assay, cell proliferation on the surface of the material is a 
vital indicator for evaluating cell cytocompatibility. The main procedure was to place 
HLC-hBMP2 porous material in a 96-well plate, to seed around 2×103 cells on each 
material, and to determine the number of cells by CCK-8 kit at different time points 
after inoculation. Meanwhile, the PBS treatment group was used as the blank control, 
the HLC treatment group was used as the negative control. This experiment therefore 
tested whether the material could promote cell proliferation. 
2.6.4 MSCs migration on the HLC-hBMP2 
To further test whether the HLC-hBMP2 and the HLC material had differential effects 
on cells, we compared cell migration on the HLC-hBMP2 and the HLC. Briefly, 5×105 
MSCs were seeded into each well of the 6-well plate with bottom coated with the HLC-
hBMP2 and the HLC, respectively. After MSCs nearly covered the bottom of the well, 
they were continually incubated with the 0.5% FBS medium for 24 hours. Then a 
straight line was drawn at the bottom of the 6-well plate covered with MSCs using a 
10-μL pipette tip. The wells were then washed 3 times with PBS until no removed and 
suspended cells were present. Images were recorded at 0, 1, 2, 3, 4 and 5 days, 
respectively for analysis. The average migration distance was calculated by measuring 
the migration area (A) and field of view height (h) using Image-J software. The 
migration distance was calculated using the following formula. 




2.7 Evaluation of bone repairing by micro CT  
Twelve Sprague Dawley (SD) rats (6-8 weeks old and 220-250g weight) were randomly 
and evenly divided into three groups: the HLC-hBMP2 fusion protein group, the HLC 
group and the without implant group as the control group. In our previous work, we 
studied the bone repairing of the HLC sponge absorbed hBMP2 in the same in vivo 
experiment [29]. To minimize the use of animals, we used the dataset obtained in that 
study to discuss and compare the bone repairing of the HLC-hBMP2 fusion protein in 
this study.  
The brief surgery process was as following: Animals were anesthetized with isoflurane. 
The hairs were removed with the 8% sodium sulfide solution, and the skin was cut from 
the midline of the skull for 20 mm to reveal the skull. The cranial drill was used to 
create an 8mm diameter hole. Subsequently, the porous material (a disc of 8mm in 
diameter and 3mm in height, approximate 30 mg) was implanted into the defect site 
and the incision was sutured layer by layer. 
After 8 weeks of implantation, the animals were sacrificed by inhalation of CO2. The 
skulls of the rats were collected, and evaluation on the cranial defect repairing was 
performed by micro-CT (Y. Cheetah, YXLON, Germany). The scanning voltage was 
80kV, the current was 50μA, and 3D reconstruction was performed at a resolution of 
10μm (VG Studio, v2.2, Volume Graphics Inc. Germany). The bone volume fraction 
(BVF) was calculated through the bone volume (BV) divided by the collected tissue 
volume (TV). The repairing rate of the cranial defect was calculated through the BVF 
of the newly formed tissue divided by the BVF of the normal calvarium.  
2.8 Evaluation of the new formed tissues 
2.8.1 Testing the amount of Col I in the new formed tissues 
The designed HLC backbone was originated from Col I and Col I was one of the main 
contents of the bone ECM. We therefore detected the amount of the Col I in the newly 
formed tissues. The animals were sacrificed 8 weeks after implantation surgery, and 
newly formed tissues were taken and frozen at -80℃ until analysis. Firstly, we milled 
the frozen tissue in liquid nitrogen to powder, and then added the RIPA lysate (Sigma, 
USA) to extract the total protein from the tissue. After quantification of the total protein 
in each tissue with the BCA kit (Thermo Scientific, USA), the same amount of the total 
protein was added to each well. Finally, the amount of the Col I in the total protein from 
each tissue were measured using the Col I Elisa Kit (Abcam, USA). 
2.8.2 Histological evaluation of the new formed tissues 
The obtained newly formed tissues were fixed in 4% paraformaldehyde. After 
decalcification, 7μm thick paraffin sections were prepared and stained with 
Hematoxylin and eosin (HE) and Masson Trichrome Staining (MTS), and then they 
were photographed by optical microscope (VHX-5000, KEYENCE, Japan). 
2.8.3 Testing bone marker proteins in tissues using immunofluorescence 
To further evaluate the repairing of bone defects, the expression of bone marker 
proteins OPN and Runx-2 were detected in new bone tissues by immunofluorescence. 
Firstly, the sectioned samples were soaked in 0.1% Triton-X100 for 10 minutes, washed 
with PBS, and blocked with 5% goat serum. Secondly, an anti-OPN antibody (host: 
mouse, Novusbio, NB110-89062SS) and anti-Runx-2 antibody (host: rabbit, Abcam, 
ab114133) were incubated overnight at 4°C. Then they were washed with PBS, and 
incubated with fluorescently labeled anti-mouse (Alexa Fluor® 488-conjugated, 
Jackson, 715-545-151) and anti-rabbit (Alexa Fluor® 594-conjugated, Jackson, 715-
585-152) secondary antibody, washed with PBS again, and stained with DAPI for 5 
minutes. Finally, the sections were observed by a laser confocal microscope (FV1000; 
Olympus Corporation, Tokyo, Japan). 
2.9 Statistical analysis 
The data was processed utilizing the SPSS20.0 statistical software package. 
Multivariate data were compared by one-way analysis of variance (ANOVA), while t-
tests were used for pairwise comparison between groups. The statistically significant 
difference was set at p<0.05.  
3. Results 
3.1 Validation of HLC-hBMP2 expression vector  
We have successfully constructed the pPIC9K-HLC-hBMP2 plasmids (Fig. 2a). To 
verify the expression vector for the HLC-hBMP2 chain, the pPIC9K-HLC-hBMP2 
plasmids were cut with restriction enzymes Xho I and Not I at the two ends of the HLC-
hBMP2 genes. Our results showed that the HLC-hBMP2 genes (band of 1619 bp) have 
been inserted into pPIC9K vectors successfully (Fig. 2b). Results of DNA sequencing 
also proved the exact connection of HLC-hBMP2 genes to the expression vector (Fig. 
S1). 
Pichia pastoris GS115 competent cells was electro-transformed by the linearized 
pPIC9K-HLC-hBMP2 plasmid, and low copy to high copy screening was performed 
by G418 resistant YPD plates. Several single colonies were randomly picked from 
G418-resistant plates and shaken overnight in YPD medium. A small amount of 
bacterial extracting genome was used as a template, and the primers of hBMP-2 was 
used to verify whether the target gene was in the strain (Fig. S2). Six strains of yeast 
expression strains were selected and transferred to BMGY medium in turn and cultured 
in BMMY medium. The culture was stopped after methanol induction for 5 days, the 
supernatant was collected by centrifugation, and the proteins were separated by SDS-
PAGE (Fig. 2c). As shown in Fig. 2c, all 6 selected strains expressed HLC-hBMP2 
fusion proteins successfully (molecular weight 51kD). In order to fully verify that the 
collected protein was the HLC-hBMP2 fusion protein, the N-terminal sequencing of 
the collected protein was performed, and the result further verified that the collected 
protein was indeed the actual HLC-hBMP2 fusion protein (Fig. S3). Based on the above 
results, the HLC-hBMP2 fusion protein was successfully expressed in the constructed 
yeast expression strain after methanol induction. 
 
Fig. 2. HLC-hBMP2 produced by pPIC9K-HLC-hBMP2 plasmids in Pichia 
pastoris GS115 and the purification process. (a) Schematic diagram of the pPIC9K-
HLC-hBMP2 plasmids; (b) Agarose gel electrophoresis of HLC-hBMP2 genes 
visualized by ethidium bromide staining. M: DNA Marker III (bp). lanes 1-4: Plasmids 
containing the HLC-hBMP2 genes digested with Xho I and Not I, producing a vector 
fragment (9.3 kb) and an HLC-hBMP2 gene fragment (1619 bp). (c) SDS-PAGE results 
showed that HLC-hBMP2 fusion protein (molecular weight 51kD) were expressed in 
all six strains of yeast. M: Protein marker (kD); lanes 1-6: the supernatant of the induced 
yeast. (d) the process of SPFF cation column purification of HLC-hBMP2 fusion 
protein shown in gel. M: Protein marker (kD); lane 1: the supernatant of fermentation 
fluid; lane 2: the post-column penetrating liquid; lane 3: the eluate after washing with 
5% B phase (containing 1 M NaCl in citric acid buffer solution); lane 4: the eluate after 
washing with 10% B phase; lane 5: the eluate after washing with 15% B phase; lane 6: 
the eluate after washing with 100% B phase. (e) Comparison of the molecular weight 
of the HLC and the HLC-hBMP2 fusion protein by SDS-PAGE. (f) Western-Blot (using 
hBMP-2 antibody): lanes 1-2: purified HLC-hBMP2 fusion protein; lanes 3-4: purified 
HLC protein. (g-j): The general morphology observation of purified HLC (g, h) and 
HLC-hBMP2 (i, j): The material was a cylinder having a diameter of 10 mm and a 
height of 5 mm; (k-n): SEM morphology observation of the HLC and HLC-hBMP2 
under different magnifications: (k) HLC and (m) HLC-hBMP2, magnified 200×; (l) 
HLC and (n) HLC-hBMP2, magnified 500×. The HLC was a layered porous structure, 
and the HLC-hBMP2 was a vertical through-hole structure by SEM.  
 
3.2 HLC-hBMP2 expression and purification 
The shaking flask culture resulted in the HLC-hBMP2 fusion protein expressed in the 
constructed yeast expression strain, and an amount of the targeted proteins was then 
obtained by high-density fermentation in a fermenter. After high-density fermentation, 
the supernatant of the fermentation fluid was collected, which contained the targeted 
HLC-hBMP2 proteins. Then the HLC-hBMP2 fusion protein was purified by SPFF 
cation column. Total protein in each purified step was shown in Fig. 2d. The first lane 
was the supernatant of the fermentation fluid after centrifuged and desalted, which 
contained lots of proteins. The second lane was the post-column penetrating liquid. 
Compared with the first lane, the band of about 51kD became lighter. This was due to 
that the target protein of 51kD size has been adsorbed on the cationic filler, and a large 
amount of the contaminants have passed through the column and flowed out. Lane 3 
was the eluate after washing with 5% B phase (containing 1 M NaCl in citric acid buffer 
solution), where the target protein was less, and the contaminants with molecular 
weight was lower than the target protein elutes. Lane 4 was the eluate after washing 
with 10% B phase, where a great deal of the target protein was eluted, and the amount 
of the contaminants was small. Lanes 5 and 6 were the eluates after washing with 15% 
B phase and 100% B phase, respectively. The purified target protein was seen in both 
Lane 5 and Lane 6 (Fig. 2d), but the volume of the eluate after washing with 100% B 
phase (Lane 6) was much less than that with 15% B phase (Lane 5). Therefore, we 
chose to collect the eluate after washing with 15% B phase and consequently obtained 
a large amount of the purified target HLC-hBMP2 fusion protein. Another reason for 
choosing the eluate after washing with 15% B phase was since the concentration of 
salts in 100% B phase was too high and made it too hard to desalt.   
Comparing the molecular weights of HLC and HLC-hBMP2 fusion proteins, the HLC-
hBMP2 fusion protein had slightly higher molecular weight than the HLC due to the 
fusion of hBMP-2 (Fig. 2e). The target protein was further detected by Western-Blot 
using hBMP-2 antibody. As shown in Fig. 2f, the purified HLC-hBMP2 fusion protein 
was observed on the membrane, however, the purified HLC did not show any band on 
the membrane. This result demonstrated that the target protein was HLC-hBMP2, 
which successfully fused with hBMP-2. At final product, the concentration of HLC-
hBMP2 was 1 g purified proteins per 1L zymotic fluid from the 150L fermenter. This 
mass production of the fusion protein made it possible to explore its clinical application.  
 
3.3 HLC-hBMP2 fusion protein fabricated a vertical through-hole structure with 
improved mechanical properties 
3.3.1 Morphological characterization of HLC-hBMP2 scaffold 
Both HLC and HLC-hBMP2 fusion proteins were soluble proteins. The morphology of 
HLC and HLC-hBMP2 after cross-linking with the EDC/NHS/MES system was shown 
in Fig. 2g-j. The material was prepared into a cylinder of 10mm in diameter and 5mm 
in height. The HLC and HLC-hBMP2 materials were all white and showed a porous 
sponge-like structure (Fig. 2g-j). The microstructure of the materials was observed by 
SEM. The HLC material had a lamellar porous structure (Fig. 2k, l), while the HLC-
hBMP2 fusion protein material was a vertical through-hole structure (Fig. 2m, n). The 
vertical pore size of porous material within the HLC-hBMP2 fusion protein was about 
100μm (Fig. 2n), which was larger than the size of the MSC. This structure therefore 
was able to facilitate the migration of MSC into the material and the delivery of 
nutrients. 
3.3.2 Improved mechanical characterization of HLC-hBMP2 scaffold  
In order to explore the processability of HLC and HLC-hBMP2 porous materials, the 
elastic modulus of the two materials were measured with a versatile analyzer (Fig. 3a, 
b). The elastic modulus of HLC-hBMP2 (1.94 ± 0.11 MPa) was significantly higher 
than that of HLC material (1.72 ± 0.02 MPa, p<0.05, n=3). The structure changes of 
the material after HLC fused with hBMP-2 was visible (Fig. 2k-n), and HLC-hBMP2 
showed vertical through-hole structure (Fig. 2m, n), which had better mechanical 
properties (Fig. 3a, b) than HLC (Fig. 2k, l) material itself. 
 
3.4 HLC-hBMP2 fusion protein retained stable properties in the mimic body fluid 
environment and accelerated degradation in the enzymatic environment. 
3.4.1 Swelling behavior 
To evaluate if the property of HLC-hBMP2 was stable in the body fluid environment, 
the swelling ratio of the HLC and the HLC-hBMP2 fusion material after forming the 
hydrogel was further tested when they were immersed into the simulated body fluid for 
different times. As shown in Table S2, HLC and HLC-hBMP2 formed hydrogels after 
immersion in PBS for 24 h. The wet weight of the HLC and the HLC-hBMP2 hydrogel 
was 8.16 ± 0.60 times and 7.79 ± 1.85 times that of the dry weight before hydrogel 
formation, respectively. There was no statistical difference between the two (p>0.05, 
n=6). After the hydrogel was formed, the swelling ratio was stabilized for 2, 4, 6, 24, 
and 48 hours, and the swelling ratio curve turned to be stable with time (Fig. 3c). In 
summary, both HLC and HLC-hBMP2 had high swelling ratio, strong water absorption 
and water retention capacity, and the swelling properties of the two materials were 
stable, and the swelling ratio tended to be stable with time. 
 
Fig. 3. Mechanical testing, swelling ratio and enzymatic degradation kinetics of the 
HLC and the HLC-hBMP2 fusion protein. (a) Compressed displacement-load curve; 
(b) Statistical results of elastic modulus (*p<0.05, n=3). (c) HLC and HLC-hBMP2 
swelling ratio curve. The hydrogel swelling ratio testing was completed in PBS solution 
at pH=7.4, and HLC and HLC-hBMP2 were immersed in PBS for 24 hours to form a 
hydrogel. The swelling ratio of the hydrogel tended to be stable, and the swelling ratio 
of the two hydrogels at each time point showed no significant difference (p>0.05, n=6). 
(d) Enzymatic degradation kinetics demonstrated no difference in susceptibility 
between the HLC and the HLC-hBMP2 to all types of collagenases (p>0.05, n=6). (e) 
The percentage of the HLC and the HLC-hBMP2 degradation was calculated according 
to the enzymatic degradation kinetics. Over 80% of the HLC or the HLC-hBMP2 were 
degraded in the Type I collagenase solution (100U/mL) within 4 hours (n=6). Compared 
with Type II collagenase or Type IV collagenase, the HLC and the HLC-hBMP2 were 
hydrolyzed significantly faster in the Type I collagenase solution (***p<0.001, n=6). 
The HLC and the HLC-hBMP2 were hydrolyzed faster in the Type II collagenase 
solution than that in the Type IV collagenase solution (***p<0.001, n=6). (f) SDS-
PAGE of the HLC-hBMP2 in Type I, Type II and Type IV collagenase solution for 4 
hours. 
3.4.2 Accelerated degradation in the enzymatic environment 
Digestion of materials in purified enzyme solution indicated that the HLC and the HLC-
hBMP2 had equal susceptibility to all types of the collagenases (Fig. 3d) but most 
susceptibility to Type I collagenase (Fig. 3d-f). Notably, most of the HLC (89.07±
8.56%, n=6) and the HLC-hBMP2 (87.37±7.36%, n=6) were degraded in the Type I 
collagenase solution (100U/mL) within 4 hours. However, only 28.91±10.77% of the 
HLC and 25.54±8.04% of the HLC-hBMP2 were degraded in the Type II collagenase 
solution (100U/mL) within 4 hours. Compared with Type I or II collagenase, the less 
HLC (14.38±3.65 %) and the less HLC-hBMP2 (14.01±4.93 %) were degraded in 
the Type IV collagenase solution (100U/mL) within 4 hours (***p<0.001, n=6, Fig. 3e). 
The HLC and the HLC-hBMP2 were the fastest and most completely hydrolyzed in the 
Type I collagenase solution (***p<0.001, n=6, Fig. 3d, e). However, it is worth to note 
that in vivo degradation is cell-mediated, and thus enzyme susceptibility may not be a 
perfect predictor for material lifetimes in vivo.  
 
3.5 HLC-hBMP2 fusion protein presented with good biocompatibility and enhanced 
MSCs migration 
3.5.1 Adhesion and proliferation of MSCs on the HLC and HLC-hBMP2 materials 
Fig. 4a-b showed the morphology of rat MSCs cultured on HLC (Fig. 4a) and HLC-
hBMP2 (Fig. 4b) fusion protein materials after 4 hours. Pseudopods protruded from 
most of the MSCs on both materials, and some of the cells have spread out and formed 
a fusiform shape (Fig. 4a-b). These results demonstrated that both materials promoted 
the adhesion of MSCs. As shown in Fig. 4c, there was no significant difference on cell 
proliferation among the HLC, the HLC-hBMP2 group and the control group (MSCs 
cultured in the cell culture plate; p>0.05, n=12). These results demonstrated that the 
HLC-hBMP2 had as good biocompatibility and no cytotoxicity as the HLC. 
3.5.2 Migration of MSCs on the HLC and the HLC-hBMP2 materials 
The rat MSCs migration on the HLC and the HLC-hBMP2 materials were quantified. 
The MSCs migration on the HLC (Day 1: 169.48±62.20 µm; Day 2: 260.69±70.43 
µm; Day 3: 414.74±61.68 µm, n=12) and the HLC-hBMP2 (Day 1: 174.29±56.25 
µm; Day 2: 274.55±67.08 µm; Day 3: 428.89±58.88 µm, n=12) had no significant 
difference at the beginning of the assay (p>0.05, n=12, Fig. 4d) until day 4. Compared 
with the HLC (509.64±79.70 µm, n=12), the HLC-hBMP2 was more permissive to 
MSCs migration at day 4 (585.25±94.98 µm, p<0.05, n=12, Fig. 4d). This result 
showed that the HLC-hBMP2 enhanced MSCs migration in the new fabricated 
structure. There was no significant difference between HLC (623.04±71.33 µm, n=12) 
and HLC-hBMP2 (624.29±86.21 µm, p>0.05, n=12, Fig. 4d) at day 5 because cells 
had fully covered the space of the cell culture plate after migration for 5 days. 
BMP2 is not only osteogenic but osteoinductive suggesting that it should drive MSC 
proliferation. However, BMP-2 cannot be released from the HLC-hBMP2 fusion 
protein without collagenase participation in our in vitro experiment. Therefore, HLC-
hBMP2 fusion protein didn’t promote the proliferation of MSC in this in vitro assay.  
Fig. 4. Adhesion, proliferation and migration of rat MSCs on the HLC and the 
HLC-hBMP2 materials. (a-b) The morphology of MSCs cultured on (a) HLC and (b) 
HLC-hBMP2 fusion protein materials for 4 hours; scanning electron microscope 
magnification: 1.5k (left) and 3k (right); (c) Proliferation assay: There was no 
significant difference on cell proliferation among the HLC group, the HLC-hBMP2 
group and the control group (rat MSCs cultured in the cell culture plate; p>0.05, n=12). 
(f) Migration assay: The migration distance of rat MSCs cultured on the HLC-hBMP2 
for 4 days was significantly higher than that of rat BMSCs cultured on the HLC (p<0.05, 
n=12). There was no significant difference between the HLC-hBMP2 group and the 
control group on the migration of MSCs at all-time points (rat BMSCs cultured on cell 
culture plates as the control; p>0.05, n=12). 
 
3.6 HLC-hBMP2 fusion protein improved cranial defects repairing in SD rats with 
controlled hBMP2 release 
3.6.1 Evaluation of bone repairing by micro CT 
The rat cranial critical size defect repair model was used in this study to investigate the 
effects of the HLC-hBMP2 on the bone regeneration in situ as previously described 
[29]. All rats survived and showed no inflammatory reactions and infections for the 
period of 8 weeks. The repairing of rat cranial defects was observed by micro-CT at the 
end of 8 weeks. After implantation of HLC-hBMP2, the repairing rate of the cranial 
defects in SD rats was significantly improved than that in both the non-implanted 
material group and the HLC material group (Fig. 5a-d). As shown in Fig. 5a-c, at 8 
weeks post operation, a small amount of bone tissue was visible along the edge of the 
defect in the control group (non-implanted material) and the HLC group, while a large 
amount of bone tissue was regenerated both at the edge of the defect and in the central 
region in the HLC-hBMP2 group. The micro-CT results showed (Fig. 5d) that after 
implantation for 8 weeks, the bone defect repair rate (51.72 ± 16.68%, n=4) in the HLC-
hBMP2 group was significantly higher than that in the HLC group (21.01 ± 14.11%, 
p<0.05, n=4) and the control group (13.63 ± 3.62%, p<0.01, n=4). There was no 
significant difference in bone defect repair rate between the HLC group and the control 
group (p>0.05, n=4). These results indicated that the HLC alone can promote bone 
defect repairing, but its repairing ability was limited. The HLC alone was not able to 
repair large-size bone defects, while the HLC-hBMP2 had the ability to repair large-
size bone defects (Fig. 5a-d). In addition, this recombinant fused HLC-hBMP2 had no 
side effects and safer for the bone repairing compared with other HLC sponge delivery 
as evidenced in our previous work [29] where TG linked HLC loaded with 5 µg rhBMP-
2 was implanted into the same rat cranial defect repair model but serious bone 
overgrowth was introduced the for 8 weeks (Fig. 8 in [29]). 
3.6.2 Col I in the new formed tissues 
Because the designed HLC backbone was originated from Col I, the composition and 
the structure of the HLC were almost the same as Col I. It is also well known that the 
Col I is one of the main contents of the bone ECM. In order to examine the degradation 
of the HLC and the HLC-hBMP2 in vivo, we therefore examined Col I in the newly 
formed tissues after implantation 8 weeks.  
The amount of Col I detected in the new formed tissues was significantly higher from 
the HLC group (460.48 ± 196.90 ng/mL) than that from the control group (193.06 ± 
63.91 ng/mL, p<0.05, n=4, Fig. 5e). While the amount of Col I from the HLC group 
was significantly less than that from the HLC-hBMP2 group (1033.12 ± 296.71 ng/mL, 
p<0.05, n=4, Fig. 5e). These results demonstrated indirectly that the HLC-hBMP2 
significantly improved bone repairing. High-resolution images with high 
magnifications (Supplement Figures 5-10) further demonstrated that chondrocytes and 
osteoclasts were clearly visible in the newly formed tissue.  
Our previous results indicated that the bone volume of the new formed tissues had no 
significant difference between the HLC group and the control group (p>0.05, n=4, Fig. 
5d) using the micro CT. This was slightly different from the above Col I Elisa testing 
results (Fig. 5e). The reasons for this difference might be: (i) the HLC was not 
completely degraded after 8 weeks implantation, which contributed to the little amount 
of the Col I detected; (ii) the Col I Elisa testing might reflect the bone formation more 
sensitively than the micro CT did. Nevertheless, the amount of Col I detected from the 




Fig. 5. Analysis of the newly formed tissues. Micro-CT scan, Col I detection and 
Histological analysis of the HLC and the HLC-hBMP2 porous materials implanted into  
SD rats with critical size defect (8mm diameter defect) after 8 weeks. Micro-CT scan 
of (a) non-implanted material, (b) implanted HLC and (c) implanted HLC-hBMP2; (d) 
Repairing rate. After implantation of the HLC-hBMP2, the repairing rate of cranial 
defects in SD rats was obviously improved than that in the non-implanted material 
group and the HLC material group (*p<0.05, **p<0.01, n=4). (e) The amount of Col I 
detected in the newly formed tissues was significantly higher from the HLC-hBMP2 
group than that from the control group (***p<0.001, n=4) or the HLC group (*p<0.05, 
n=4). While the amount of Col I detected in the newly formed tissues from the HLC 
group was significantly higher than that from the control group (*p<0.05, n=4). HE 
stain of (f) the control group (non-implanted material); (g) the HLC group; (h) the HLC-
hBMP2 group, and MTS of (i) the control group (non-implanted material); (j) the HLC 
group; (k) the HLC-hBMP2 group. Three different repaired defect sites were chosen 
from all groups and labelled as 1-3 from left to right. The zoomed-out of chosen parts 
were shown below accordingly. 
 
3.6.3 Histological and immunofluorescence evaluation of new formed tissues 
After the implantation of the samples in the rat skull defect model, we observed its 
repairing effects for various time periods, including a shorter time scale of 2 weeks and 
4 weeks, but no significant changes were observed in these early period times after 
surgery. The significant difference only appeared till after 8 weeks of implantation. At 
8 weeks post operation, the samples of repaired tissues from all groups were analyzed 
by histochemistry. The osteogenesis of the new tissue formed from all groups at the 
defect site was observed by HE stain (Fig. 5f-h) and MTS (Fig. 5i-k). The results 
showed that only a thin layer of fibrous tissue in the defect site was formed in the control 
group (Fig. 5f, i). In the HLC group, a small amount of bone tissue was formed in the 
middle of the defect site (Fig. 5g, j). While in the HLC-hBMP2 group, continuous new 
bone tissue was formed in nearly all defect sites and many collagens were observed. In 
addition, the HLC-hBMP2 material has completely degraded (Fig. 5h, k). 
Runx-2 is a transcription factor related to mesenchymal commitment to the osteogenic 
lineage. Runx-2 is also a preosteoblast marker [34] which could be detected in the early 
stage of stem cell differentiation to osteogenesis. Due to the slow releasing of the BMP-
2 from our novel device HLC-hBMP2 in this study, the defect areas have not been 
completely repaired at the 8th week after intervention, so we inferred that the stem cell 
differentiation to osteogenesis could have still been happening in the defect site after 8 
weeks of implantation.  
To compare the levels of the osteoblast markers in the new tissue samples from the 
different groups, the expression of the pre-osteoblastic marker Runx-2 [34], osteoblast 
marker OPN were analyzed by immunofluorescence staining. At 8 weeks post 
operation, the pre-osteoblastic marker Runx-2 was not expressed in the control group 
and the HLC group, whereas Runx-2 was found in the HLC-hBMP2 group (Fig. 6a). 
The osteoblast marker OPN was not expressed in the control group, but in both the HLC 
group and the HLC-hBMP2 group (Fig. 6a), yet the expression of OPN in the HLC 
group (3.87 ± 1.45%, n=4) was significantly less than that in the HLC-hBMP2 group 
(9.58 ± 2.81%, *p<0.05, n=4, Fig. 6b). These results suggested that the HLC-hBMP2 
significantly improved bone repairing. 
 
Fig. 6. Immunofluorescence analysis of the expression of bone marker proteins in 
the newly formed tissues from rat skull with standard aperture defect at 8 weeks 
post-operation. (a) Tissue sections of the HLC group and HLC-hBMP2 group were 
immunofluorescent stained with antibodies to OPN and Runx-2 bone marker proteins 
respectively, DAPI stained with blue, OPN protein labeled with green fluorescence 
while Runx-2 protein with red fluorescence. (b) Quantitative analysis of OPN and 
Runx-2 expression in each group (**p<0.01, n=4). 
3.6.4 Histological evaluation of HLC-hBMP2 fusion protein degraded and released 
hBMP2 in vivo 
In order to verify that HLC-hBMP2 fusion protein degraded and released hBMP-2 in 
vivo, the presence of BMP-2 in new bone tissue was detected by immunofluorescence. 
The primary antibody used was anti-BMP-2 antibody (host: rabbit, Abcam, ab14933), 
the secondary antibody used was goat anti-rabbit antibody (Alexa Fluor® 488-
conjugated, Jackson, Lot: 137875), and the samples were stained with DAPI. In the end, 
photographs were taken with a laser confocal microscope (FV1000; Olympus 
Corporation, Tokyo, Japan). As shown in Fig. 7, after the implantation of the HLC-
hBMP2 material for 8 weeks, hBMP2 (2.93 ± 2.12%, n=4) aggregated on one side of 
the new bone near the rat brain tissue, which confirmed that hBMP2 released after HLC 
degradation in the HLC-hBMP2. In particular, the HLC group also formed a small 
amount of bone tissue in the defect (Fig. 5-6), but hBMP2 was not detected in this bone 
tissue (Fig. 7), which further confirmed that hBMP2 in the HLC-hBMP2 group was not 
produced by the body itself but was released by material degradation. In addition, 
except for the surrounding of the new form tissue, we didn’t detect the BMP-2 existing 
in the blood or other tissues of the rats. This may be due to the very low dose of BMP-
2 released from the HLC-hBMP2 fusion protein and indirectly proved a controlled 
release of our novel device. 
 
Fig. 7. Immunofluorescence analysis of hBMP2 expression in the newly formed 
tissues from rat skull with standard aperture defect at 8 weeks post operation. (a) 
Tissue sections of the HLC group and the HLC-hBMP2 group were immunofluorescent 
stained with hBMP2 antibody. The nucleus was stained blue by DAPI and hBMP2 was 




There are normally two ways to improve the potency and efficacy of BMPs in bone 
repairing. One way is to modify BMPs as a dimer structurally or to use point mutants 
with improved properties [35-38]. Another way is to introduce carriers with optimized 
material and structural properties to optimize BMP retention and to improve BMP 
presentation to responding cells [39]. 
In this study, we took the second route to create the HLC-hBMP2 fusion protein 
scaffold which showed a different microstructure from the HLC scaffold after 
constructed by the gradient vacuum freeze-drying method. The HLC scaffold had a 
layered porous structure, while the HLC-hBMP2 scaffold presented with an 
omnidirectional through-hole structure (Fig. 2m, n). The elastic modulus of the HLC-
hBMP2 scaffold with omnidirectional through-hole structure was markedly higher than 
that of the HLC scaffold, and thus improved its mechanical properties (Fig. 3a, b). 
Moreover, this vertical through-hole structure was beneficial for facilitating the 
migration of MSCs into the HLC-hBMP2 fusion material, and therefore HLC-hBMP2 
enhanced MSCs migration (Fig. 4d).  
In addition, HLC-hBMP2 showed stronger bone defect repairing ability in vivo than 
HLC alone. Eight weeks after the implantation of the two scaffolds into the cranial 
defect site in the rats, the bone defect repairing rate of the HLC-hBMP2 group (51.72 
± 16.68%, n=4) was significantly higher than that of the HLC group (21.01 ± 14.11%, 
p<0.05, n=4) and the control group (13.63 ± 3.62%, p<0.01, n=4, Fig. 5). These results 
demonstrated HLC-hBMP2 can successfully repair large size bone defects. In addition, 
there was no inflammatory reaction and infection during this repairing process. 
The results from in vitro assays showed that HLC and HLC-hBMP2 had no 
significantly different effects on cell adhesion and proliferation (Fig. 4 and Fig. S4), 
confirming that HLC-hBMP2 fusion protein had no osteoinductive activity in vitro. The 
reason for this is that hBMP-2 can play a role in osteolysis only through forming a 
dimer [3, 40], either heterodimeric BMPs or homodimeric BMP chimeras [35-38]. The 
reason why HLC-hBMP2 in this study did not form a dimer in vitro was due to the fact 
that HLC with a large molecular weight was attached to the C-terminus of hBMP-2 and 
made it impossible to form the dimer (Fig. 1). Yet, the results from in vivo assays 
revealed that the HLC-hBMP2 fusion protein can exert osteoinductive function and 
promoted the bone repairing rate to 51.72 ± 16.68% compared to the control group 
(13.63 ± 3.62%, p<0.01, n=4, Fig. 5-7) after implantation for 8 weeks. Actually, studies 
have shown that BMP signaling is complex in vivo due to the complicated dimer nature 
of the BMP ligands involved in signal transduction [35, 41, 42]. Besides, the role of 
potential responding cells in bone repairing from the periosteum, bone marrow, 
muscle/fascia, and vasculature may play a role although this role still remains unclear 
[43]. Therefore, it is crucial to determine the exact role of BMP-2 not only in vitro but 
also in the complex internal environment. The repairing effects for the period of 8 
weeks implant was particularly evaluated in this study. This was based on our previous 
work [29] on the BMP2 release profile and for the comparison purpose. The traumatic 
bone animal model won’t automatically repair within 8 weeks but can be reasonably 
repaired with purposely designed implants. The longitudinal and cross sections 
evaluation of the release of implants for bone repairing at different time scale in the 
future certainly would help to utilize the efficiency of this fused protein.  
In our study, enzymatic degradation was used as an accelerated measurement of 
material degradation. Most of the HLC-hBMP2 were degraded in the Type I 
collagenase solution within 4 hours in vitro (Fig. 3e, f). Combined with in vivo assays, 
we inferred that the HLC in the HLC-hBMP2 fusion protein was enzymatically 
degraded slowly within 8 weeks. This was based on the observation of a significantly 
different amount of Col I detected in the newly formed tissues from all three groups 
(Fig. 5e). In addition, hBMP2 aggregated on one side of the new bone near the rat brain 
tissue after the implantation of the HLC-hBMP2 material for 8 weeks but it was not 
detected in the new bone from the HLC group. This further confirmed that hBMP2 was 
released from HLC-hBMP2 after the HLC degradation in vivo (Fig. 7).  
In our previous study, the HLC sponge (linked through TG) was used as a delivery 
system to release hBMP-2 [29]. HLC sponge containing 5μg hBMP-2 released 15.03 ± 
3.92% of hBMP-2 at day 1, 18.61 ± 2.61% at day 2 and 48.19 ± 8.69% at day 28. The 
HLC sponge containing 1μg hBMP-2 released 9.74 ± 1.56% at day 1, 18.13 ± 2.34% 
at day 3, and 44.79 ± 10.43% at day 28 [29]. In the current study, we did the same 
assays for hBMP2 release from the HLC-hBMP2 fusion scaffold in vitro using the same 
immersion solution (PBS), time points (1, 2, 3, 5, 7, 14, 21 and 28 days) and ELISA kit 
(Human BMP2 ELISA Kit, Abcam, ab119581, Lot GR3174552-1). However, the dose 
of released hBMP-2 was very low and barely detectable in vitro (data not shown). 
Perhaps it couldn’t be released from the HLC-hBMP2 fusion scaffold due to the 
collagenase not present in vitro but only can be slowly released in vivo where 
collagenase was presented. But verification and measurement of hBMP2 release from 
fused protein in vivo turned out to be very challenging and we are not able to claim how 
exactly this release was achieved in the present study (data not shown and see 
discussion below). Nevertheless, our results showed that the fused HLC-hBMP2 
improved bone regeneration. 
Based on the above, we speculated that accompanying with the HLC degradation, the 
hBMP-2 can be controllably released and may form a dimer in vivo and then exert its 
osteogenic activity. As shown in Fig. 8, the HLC from the HLC-hBMP2 fusion protein 
was slowly hydrolyzed in vivo, which suggested a delayed process of releasing hBMP-
2, and this in turn resulted in a stable release and better efficacy of hBMP-2 in bone 
repairing (Fig. 5-8). This result was different from our previous work which HLC 
sponge loaded with hBMP-2 for the rat cranial defect repair [29]. The HLC sponge 
loaded with hBMP-2 introduced rapid release but serious bone overgrowth occurred 
after implantation when loaded with a high dose of hBMP-2 (i.e. 5µg) [29]. These were 
also reflected in the measurements of osteoblast differentiation markers (Preosteoblast 
marker: Runx-2; Osteoblast marker: OPN) in repaired tissue correspondingly (Fig.8 in 
[29]). 
  
Fig. 8. Sketch of bone formation accompanied with hBMP2 release. (a) The vertical 
through-hole structure of HLC-hBMP2 enhanced cell migration into the scaffold; (b) 
Cell invaded and settled in the porous scaffold accompanied with HLC being degraded 
by Collagenase from the HLC-hBMP2 in vivo. (c) HLC was degraded and hBMP-2 was 
released from the HLC-hBMP2. The hBMP-2 formed dimer which improved 
osteogenic differentiation of cells. (d) The new bone formed and the HLC-hBMP2 was 
finally enzymatically degraded into amino acid (AA). 
Compared with this previous work, the slow release of hBMP-2 from the HLC-hBMP2 
fusion protein accompanying with the collagenase degradation in vivo achieved in this 
study was beneficial for a gentler and safer osteogenesis. We speculate that the unique 
structure of HLC-hBMP2 fusion protein may contribute to this, i.e. the HLC-hBMP2 
fusion protein structure helped the stability of BMP2 or retained in the fusion protein; 
active BMP-2 was then sustained and controlled releas from the fusion through 
enzymatic degradation in vivo. The spatial and temporal control of the hBMP-2 release 
from the HLC-hBMP2 fusion protein in the bone defect repairing can be further 
achieved by designing a degradable linker between the HLC and the hBMP-2. The 
function of this linker is to controllably degrade in a specific internal environment and 
then release the hBMP-2 from the HLC-linker-hBMP2. The exact design of this linker 
could be a disulfide bonder (LEAGCKNFFPR↓SFTSCGSLE) to be inserted into a 
thrombin-sensitive sequence, a disulfide to be inserted into a protease-sensitive 
sequence, a dithiocyclic peptide linker (CRRRRRR↓EAEEAC) inserting protease 
sensitive sequence, etc. Through using the degradable linker and adjusting the localized 
microenvironment at the same time, such as adjusting the localized concentration of 
proteases, the hBMP-2 release could be further controlled to improve its efficacy in 
bone repairing. 
The idea of using fusion protein as a delivery vehicle to effectively control the release 
of growth factors have been reported but mainly on the skin defects repairing [44-49]. 
However, fusion protein has not been applied in bone defect repairing, apart from one 
study using Elastin-like-polypeptide [50]. In this study, we successfully designed the 
HLC-hBMP2 fusion protein and used it to repair the bone defect for the first time. The 
construction of the HLC-hBMP2 fusion protein in our study had several advantages. 
Firstly, the HLC-hBMP2 fusion protein was a direct product, and this avoided the 
inactivation of hBMP-2 in the process of complexing with the HLC and therefore 
retained its stable osteogenic activity; Secondly, the designed HLC gene code in the 
HLC-hBMP2 fusion protein can be modified and controlled, and this resulted in a 
unique vertical through-hole structure of HLC-hBMP2 with the larger elastic modulus 
(Fig. 2-3), a slow HLC degradation accompanying with the hBMP-2 stable release (Fig. 
5-8), and some enhanced properties compared to animal tissue-extracted collagens 
when loaded with BMP-2 (Table S3). Thirdly, because the gene code in the HLC-
hBMP2 was originated from the human gene code, the recombinant HLC-hBMP2 
fusion protein produced thus had little potential virus risk and immunogenicity. In in 
vivo study, rats in all groups survived throughout the experiments, and there were no 
visible inflammatory reactions, infections or extrusions around the implantation sites 
observed, and there was none of the inflammatory cell infiltration shown in the 
supplementary images at high magnification (Fig. S5-7). Immunofluorescence staining 
also indicated that no CD206+ macrophages existed in the newly formed tissues after 
implantation 8 weeks (Fig. S11). All these indicated good biocompatibility of the 
scaffolds. Fourthly, the fused HLC-hBMP2 has no side effects and proved to be safer 
than other previous HLC-hBMP2 delivery systems (i.e. absorbing through TG links, 
Fig. 8 in [29]). All these proved that the HLC-hBMP2 had osteoinductive activity and 
promoted bone healing better than the traditional simple superposition of the hBMP-
2/collagen sponge would do.  
5. Conclusions 
In this study, we constructed a novel HLC-hBMP2 fusion protein and successfully 
applied it in the bone repairing for the first time. This novel HLC-hBMP2 fusion protein 
formed a vertical through-hole structure with a larger elastic modulus compared with 
that of the HLC only scaffold. This unique structure of the HLC-hBMP2 scaffold 
facilitated the migration of MSCs into the material and the delivery of nutrients through 
the hole. As a novel delivery system for hBMP2, the HLC-hBMP2 fusion protein can 
controllably release hBMP-2 in vivo and thus have the stable osteogenic activity to 
promote healing of the rat cranial large size defect. Besides, this recombinant HLC-
hBMP2 had little potential virus risk and immunogenicity compared with the normal 
commercial collagen sponges extracted from the animal tissues. Therefore, this novel 
recombinant fusion protein could be more beneficial in the treatment of bone defects 
than the simple superposition of the hBMP2/collagen sponge. In addition, the method 
developed in this study to create the fusion protein overcame the high product costs and 
could be readily extended to produce other growth factors or therapeutic proteins. 
Furthermore, the design of the linker between HLC and hBMP-2 would contribute to 
achieving the spatial and temporal control of the HLC-hBMP2 fusion protein in the 
completion of bone defect repairing.  
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Fig. S3: The N-terminal sequencing result of the HLC-hBMP2 fusion protein.  
Fig. S4: Adhesion, proliferation and migration of rabbit MSCs on the HLC and the 
HLC-hBMP2 materials. 
Fig. S5: H&E staining of the control sample at high magnification. 
Fig. S6: H&E staining of HLC sample at high magnification. 
Fig. S7: H&E staining of HLC-hBMP2 sample at high magnification. 
Fig. S8: MTC staining of the control sample at high magnification. 
Fig. S9: MTC staining of HLC sample at high magnification. 
Fig. S10: MTC staining of HLC-hBMP2 sample at high magnification. 
Fig. S11: Immunofluorescence analysis of CD206 in the newly formed tissues from rat 
skull with standard aperture defect at 8 weeks post operation. 
Table S1: Culture conditions and culture media in the fermentor. 
Table S2: The raw data of the swelling rate stability test for the HLC and HLC-hBMP2.  
Table S3: Comparison between the commercial collagen sponges loaded with BMP-2 
and the recombinant HLC-hBMP2 fusion materials.  
 
Declaration of conflicting of interests 
The authors declare no conflict of interest. 
 
Acknowledgements 
This work was supported by the National Natural Science Foundation of P. R. China 
(No. 21706212 to Z.Y.C, and No. 21838009 to D.D.F). Special Support Plan for High-
level Talents, and Innovation Team Program in Shaanxi Province. 
 
ORCID iDs 
Zhuoyue Chen http://orcid.org/0000-0003-0590-2401 
Lijun Shang http://orcid.org/0000-0001-5925-5903 
Daidi Fan http://orcid.org/0000-0001-9798-1674 





 [1] B. Poon, T. Kha, S. Tran, C.R. Dass, Bone morphogenetic protein-2 and bone therapy: successes 
and pitfalls. Journal of Pharmacy & Pharmacology 68(2) (2016) 139. 
 [2] U. Ripamonti, R. Duarte, R. Parak, C. Dickens, T. Dix-Peek, R.M. Klar, Redundancy and Molecular 
Evolution: The Rapid Induction of Bone Formation by the Mammalian Transforming Growth Factor-β
3 Isoform. FRONT PHYSIOL 7 (2016) 396. 
 [3] Z. Sheikh, M.A. Javaid, N. Hamdan, R. Hashmi, Bone Regeneration Using Bone Morphogenetic 
Proteins and Various Biomaterial Carriers. MATERIALS 8(4) (2015) 1778-1816. 
 [4] S. Saini, A.J. Duraisamy, S. Bayen, P. Vats, S.B. Singh, Role of BMP7 in appetite regulation, 
adipogenesis, and energy expenditure. ENDOCRINE 48(2) (2015) 405-409. 
 [5] D. Katanec, M. Granic, M. Majstorovic, Z. Trampus, D.G. Panduric, Use of recombinant human 
bone morphogenetic protein (rhBMP2) in bilateral alveolar ridge augmentation: case report. Coll 
Antropol 38(1) (2014) 325-330. 
 [6] C. Bibbo, J. Nelson, D. Ehrlich, B. Rougeux, Bone morphogenetic proteins: indications and uses. 
Clin Podiatr Med Surg 32(1) (2015) 35-43. 
 [7] I. El Bialy, W. Jiskoot, M. Reza Nejadnik, Formulation, Delivery and Stability of Bone 
Morphogenetic Proteins for Effective Bone Regeneration. PHARM RES-DORDR 34(6) (2017) 1152-
1170. 
 [8] I. Brigaud, R. Agniel, J. Leroy-Dudal, S. Kellouche, A. Ponche, T. Bouceba, N. Mihailescu, M. 
Sopronyi, E. Viguier, C. Ristoscu, F. Sima, I.N. Mihailescu, A.C.O. Carreira, M.C. Sogayar, O. Gallet, 
K. Anselme, Synergistic effects of BMP-2, BMP-6 or BMP-7 with human plasma fibronectin onto 
hydroxyapatite coatings: A comparative study. ACTA BIOMATER 55 (2017) 481-492. 
 [9] G.H. Lee, P. Makkar, K. Paul, B. Lee, Development of BMP-2 immobilized polydopamine 
mediated multichannelled biphasic calcium phosphate granules for improved bone regeneration. 
MATER LETT 208 (2017) 122-125. 
[10] Z.Y. Chen, Z. Zhang, J.T. Feng, Y.Y. Guo, Y. Yu, J.H. Cui, H.M. Li, L.J. Shang, The influence of 
Mussel-Derived Bioactive BMP-2 decorated PLA on MSCs behavior in vitro and verification with 
osteogenicity at ectopic sites in vivo. ACS APPL MATER INTER 10 (2018) 11961-11971. 
[11] S.S. Lee, B.J. Huang, S.R. Kaltz, S. Sur, C.J. Newcomb, S.R. Stock, R.N. Shah, S.I. Stupp, Bone 
regeneration with low dose BMP-2 amplified by biomimetic supramolecular nanofibers within collagen 
scaffolds. BIOMATERIALS 34(2) (2013) 452-459. 
[12] L.B. Priddy, O. Chaudhuri, H.Y. Stevens, L. Krishnan, B.A. Uhrig, N.J. Willett, R.E. Guldberg, 
Oxidized alginate hydrogels for BMP-2 delivery in long bone defects. ACTA BIOMATER 10(10) (2014) 
4390-4399. 
[13] Q. Min, X. Yu, J. Liu, J. Wu, Y. Wan, Chitosan-Based Hydrogels Embedded with Hyaluronic Acid 
Complex Nanoparticles for Controlled Delivery of Bone Morphogenetic Protein-2. Pharmaceutics 
 11(5) (2019) 214. 
[14] J. Wu, L. Li, C. Fu, F. Yang, Z. Jiao, X. Shi, Y. Ito, Z. Wang, Q. Liu, P. Zhang, Micro-porous 
polyetheretherketone implants decorated with BMP-2 via phosphorylated gelatin coating for enhancing 
cell adhesion and osteogenic differentiation. Colloids and Surfaces B: Biointerfaces 169 (2018) 233-241. 
[15] M. Yamamoto, A. Hokugo, Y. Takahashi, T. Nakano, M. Hiraoka, Y. Tabata, Combination of 
BMP-2-releasing gelatin/β-TCP sponges with autologous bone marrow for bone regeneration of X-ray-
irradiated rabbit ulnar defects. BIOMATERIALS 56 (2015) 18-25. 
[16] Z. Wang, Z. Wang, W.W. Lu, W. Zhen, D. Yang, S. Peng, Novel biomaterial strategies for 
controlled growth factor delivery for biomedical applications. NPG ASIA MATER 9(10) (2017) 435. 
[17] E. Lee, H. Lim, J. Hong, J. Lee, U. Jung, S. Choi, Bone regenerative efficacy of biphasic calcium 
phosphate collagen composite as a carrier of rhBMP-2. CLIN ORAL IMPLAN RES 27(11) (2016) 91-
99. 
[18] H. Lu, N. Kawazoe, T. Kitajima, Y. Myoken, M. Tomita, A. Umezawa, G. Chen, Y. Ito, Spatial 
immobilization of bone morphogenetic protein-4 in a collagen-PLGA hybrid scaffold for enhanced 
osteoinductivity. BIOMATERIALS 33(26) (2012) 6140-6146. 
[19] G. Bhakta, Z.X.H. Lim, B. Rai, T. Lin, J.H. Hui, G.D. Prestwich, A.J.V. Wijnen, V. Nurcombe, 
S.M. Cool, The influence of collagen and hyaluronan matrices on the delivery and bioactivity of bone 
morphogenetic protein-2 and ectopic bone formation. ACTA BIOMATER 9(11) (2013) 9098-9106. 
[20] J. Zhao, M. Shinkai, T. Takezawa, S. Ohba, U. Chung, T. Nagamune, Bone regeneration using 
collagen type I vitrigel with bone morphogenetic protein-2. J BIOSCI BIOENG 107(3) (2009) 318-323. 
[21] R.J. Mannion, A.M. Nowitzke, M.J. Wood, Promoting fusion in minimally invasive lumbar 
interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost? Spine Journal 
Official Journal of the North American Spine Society 11(11) (2011) 527-533. 
[22] M. Miyazaki, Y. Morishita, W. He, M. Hu, C. Sintuu, H.J. Hymanson, J. Falakassa, H. Tsumura, 
J.C. Wang, A porcine collagen-derived matrix as a carrier for recombinant human bone morphogenetic 
protein-2 enhances spinal fusion in rats. The Spine Journal 9(1) (2008) 22-30. 
[23] B. Chen, H. Lin, J. Wang, Y. Zhao, B. Wang, W. Zhao, W. Sun, J. Dai, Homogeneous osteogenesis 
and bone regeneration by demineralized bone matrix loading with collagen-targeting bone 
morphogenetic protein-2. BIOMATERIALS 28(6) (2007) 1027-1035. 
[24] M.S. Kumar, S. Kirubanandan, R. Sripriya, P.K. Sehgal, Triphala incorporated collagen sponge--a 
smart biomaterial for infected dermal wound healing. J SURG RES 158(1) (2010) 162. 
[25] H. Begam, S.K. Nandi, B. Kundu, A. Chanda, Strategies for delivering bone morphogenetic protein 
for bone healing. Mater Sci Eng C 70(1) (2017) 856-869. 
[26] X. Jiang, Y. Wang, D. Fan, C. Zhu, L. Liu, Z. Duan, A novel human-like collagen hemostatic 
sponge with uniform morphology, good biodegradability and biocompatibility. J BIOMATER APPL 
31(8) (2017) 1099-1107. 
[27] L. Zhao, L. Xian, J. Zhao, S. Ma, X. Ma, D. Fan, C. Zhu, Y. Liu, A novel smart injectable hydrogel 
prepared by microbial transglutaminase and human-like collagen: Its characterization and 
biocompatibility. Materials Science & Engineering C 68 (2016) 317-326. 
[28] C. Zhu, D. Fan, Y. Wang, Human-like collagen/hyaluronic acid 3D scaffolds for vascular tissue 
engineering. Materials Science & Engineering C 34(1) (2014) 393-401. 
[29] Z. Chen, Z. Zhang, X. Ma, Z. Duan, J. Hui, C. Zhu, D. Zhang, D. Fan, L. Shang, F. Chen, Newly 
Designed Human-like Collagen to Maximize Sensitive Release of BMP-2 for Remarkable Repairing of 
Bone Defect. Biomolecules 9(9) (2019) 450. 
[30] P.A. Parmar, S.C. Skaalure, L.W. Chow, J.P. St-Pierre, V. Stoichevska, Y.Y. Peng, J.A. 
Werkmeister, J.A. Ramshaw, M.M. Stevens, Temporally degradable collagen-mimetic hydrogels tuned 
to chondrogenesis of human mesenchymal stem cells. BIOMATERIALS 99 (2016) 56-71. 
[31] A.H. Morris, D.K. Stamer, B. Kunkemoeller, J. Chang, H. Xing, T.R. Kyriakides, Decellularized 
materials derived from TSP2-KO mice promote enhanced neovascularization and integration in diabetic 
wounds. BIOMATERIALS 169 (2018) 61-71. 
[32] Z. Chen, J. Wei, J. Zhu, W. Liu, J. Cui, H. Li, F. Chen, Chm-1 gene-modified bone marrow 
mesenchymal stem cells maintain the chondrogenic  phenotype of tissue-engineered cartilage. STEM 
CELL RES THER 7(1) (2016) 70. 
[33] Z. Chen, S. Yue, Z. Jing, L. Wei, J. Cui, H. Li, F. Chen, Laminated electrospun nHA/PHB-
composite scaffolds mimicking bone extracellular matrix for bone tissue engineering. Mater Sci Eng C 
Mater Biol Appl 72 (2017) 341-351. 
[34] F. Knopf, C. Hammond, A. Chekuru, T. Kurth, S. Hans, C.W. Weber, G. Mahatma, S. Fisher, M. 
Brand, S. Schulte-Merker, G. Weidinger, Bone regenerates via dedifferentiation of osteoblasts in the 
zebrafish fin. DEV CELL 20(5) (2011) 713-724. 
[35] D. Yadin, P. Knaus, T.D. Mueller, Structural insights into BMP receptors: Specificity, activation 
and inhibition. CYTOKINE GROWTH F R 27 (2016) 13-34. 
[36] K. Schmidt-Bleek, B.M. Willie, P. Schwabe, P. Seemann, G.N. Duda, BMPs in bone regeneration: 
Less is more effective, a paradigm-shift. CYTOKINE GROWTH F R 27 (2016) 141-148. 
[37] J.W. Lowery, B. Brookshire, V. Rosen, A Survey of Strategies to Modulate the Bone 
Morphogenetic Protein Signaling Pathway: Current and Future Perspectives. STEM CELLS INT 
2016(30) (2016) 1-15. 
[38] Y. Byung-Hak, E. Luis, A. Chihoon, P.C. Gray, Y. Sang-Kyu, K. Witek, C. Senyon, An activin 
A/BMP2 chimera, AB204, displays bone-healing properties superior to those of BMP2. Journal of Bone 
& Mineral Research 29(9) (2015) 1950-1959. 
[39] E. Migliorini, A. Valat, C. Picart, E.A. Cavalcanti-Adam, Tuning cellular responses to BMP-2 with 
material surfaces. CYTOKINE GROWTH F R 27 (2016) 43-54. 
[40] J.M. Granjeiro, R.C. Oliveira, J.C. Bustos-Valenzuela, M.C. Sogayar, R. Taga, Bone 
morphogenetic proteins: from structure to clinical use. Brazilian Journal of Medical & Biological 
Research 38(10) (2005) 1463-1473. 
[41] H. Kai, A. Seher, W. Schmitz, T.D. Mueller, W. Sebald, J. Nickel, Receptor oligomerization and 
beyond: a case study in bone morphogenetic proteins. BMC Biology,7,1(2009-09-07) 7(1) (2009) 59. 
[42] M.J. Isaacs, Y. Kawakami, G.P. Allendorph, B.H. Yoon, J.C.I. Belmonte, S. Choe, Bone 
morphogenetic protein-2 and -6 heterodimer illustrates the nature of ligand-receptor assembly. MOL 
ENDOCRINOL 24(7) (2010) 1469-1477. 
[43] H.J. Seeherman, S.P. Berasi, C.T. Brown, R.X. Martinez, Z.S. Juo, S. Jelinsky, M.J. Cain, J. Grode, 
K.E. Tumelty, M. Bohner, O. Grinberg, N. Orr, O. Shoseyov, J. Eyckmans, C. Chen, P.R. Morales, C.G. 
Wilson, E.J. Vanderploeg, J.M. Wozney, A BMP/activin A chimera is superior to native BMPs and 
induces bone repair in nonhuman primates when delivered in a composite matrix. SCI TRANSL MED 
11(489) (2019) 1-20. 
[44] I. Elloumi, R. Kobayashi, H. Funabashi, M. Mie, E. Kobatake, Construction of epidermal growth 
factor fusion protein with cell adhesive activity. BIOMATERIALS 27(18) (2006) 3451-3458. 
[45] P. Koria, H. Yagi, Y. Kitagawa, Z. Megeed, Y. Nahmias, R. Sheridan, M.L. Yarmush, Self-
assembling elastin-like peptides growth factor chimeric nanoparticles for the treatment of chronic 
wounds. P NATL ACAD SCI USA 108(3) (2011) 1034-1039. 
[46] A. Yeboah, The use of stromal cell derived growth factor 1-elastin like peptide fusion protein 
nanoparticles to improve chronic skin wounds. Ph.D. Dissertation (2016). 
[47] A. Yeboah, T. Maguire, R. Schloss, F. Berthiaume, M.L. Yarmush, Stromal Cell-Derived Growth 
Factor-1 Alpha-Elastin Like Peptide Fusion Protein Promotes Cell Migration and Revascularization of 
Experimental Wounds in Diabetic Mice. ADV WOUND CARE 6(1) (2017) 10-22. 
[48] J. Yang, W. Qiang, S. Ren, S. Yi, J. Li, L. Guan, L. Du, Y. Guo, H. Hu, H. Li, High-efficiency 
production of bioactive oleosin-basic fibroblast growth factor in A. thaliana  and evaluation of wound 
healing. GENE 639 (2017) 69-76. 
[49] J. Cai, R. Wen, W. Li, X. Wang, H. Tian, S. Yi, L. Zhang, X. Li, C. Jiang, H. Li, Oil body bound 
oleosin-rhFGF9 fusion protein expressed in safflower (Carthamus tinctorius L.) stimulates hair growth 
and wound healing in mice. BMC BIOTECHNOL 18(1) (2018) 51. 
[50] McCarthy B, Yuan Y, Koria P. Elastin-like-polypeptide based fusion proteins for osteogenic factor 
delivery in bone healing. BIOTECHNOL PROG. 32(4) (2016) 1029-1037.  
 
